The clinical backdrop is significant. Sarcopenia, the progressive loss of muscle mass, strength and function that accompanies ageing, is now formally recognized by the World Health Organization as a disease in its own right. Its prevalence climbs steeply with age, reaching up to 29 percent of older adults in community settings and between 11 and 50 percent of people aged 80 and above. Beyond ageing itself, risk factors include low protein intake, malabsorption, physical inactivity, metabolic and endocrine disorders, and hospitalization. Crucially, no drug has been approved to treat the condition. Current management relies on exercise, caloric control and nutritional supplementation, while experimental pharmacological approaches such as selective androgen receptor modulators and myostatin inhibitors have focused mainly on increasing muscle mass rather than restoring strength. That gap has pushed researchers toward dietary compounds that might support muscle function at the cellular level, and urolithins have emerged as leading candidates.

Urolithin A already has a track record in muscle research. Previous preclinical and clinical studies have shown that it promotes mitophagy, the cellular housekeeping process that clears damaged mitochondria, thereby improving mitochondrial quality and muscle function. Urolithin B has attracted less attention, though recent work identified it as a regulator of skeletal muscle mass that promotes the differentiation and hypertrophy of myotubes, the multinucleated fibers that form in culture when muscle stem cells mature. Some studies also suggest urolithin B exerts testosterone-like effects that tip muscle protein balance toward growth. What remained unknown was how the two molecules compare when applied to genuine human muscle cells under identical conditions, and whether their effects converge on shared pathways or diverge into entirely different biology.

To find out, the researchers isolated satellite cells, the resident stem cells of skeletal muscle, from biopsies of the vastus lateralis muscle taken post-mortem from nine donors aged between 55 and 96, with ethical approval from the University of Liège. The cells were purified using immunomagnetic sorting for the satellite cell marker CD56, expanded in culture, and then differentiated for 48 hours into myotubes, a transition confirmed by measuring myogenic markers such as myosin. The mature myotubes were treated for 24 hours with either urolithin A or urolithin B at a concentration of 5 micromolar, a dose chosen to balance biological activity with physiological plausibility, since pharmacokinetic studies indicate that urolithin A can reach low micromolar levels in human plasma after supplementation. The team then sequenced the entire transcriptome of each sample, generating roughly 20 million reads per sample and analyzing differential gene expression with a paired statistical design that accounted for donor-to-donor baseline differences.

The scale of the response differed dramatically between the two compounds. Urolithin A significantly altered the expression of 1,918 genes, whereas urolithin B affected only 339. Despite this imbalance, 180 genes were regulated by both molecules, with 162 commonly down-regulated and 18 commonly up-regulated, pointing to shared effects that likely stem from their well-documented antioxidant and anti-inflammatory properties. More intriguing were the nine genes that moved in opposite directions. Eight genes, including EPB41L1, JPH1, GOT1, IL-17B, ESYT1, BEAN1, PCSK9 and SLCO4C1, were pushed up by urolithin B and pulled down by urolithin A, while a single gene, NQO1, was up-regulated by urolithin A and down-regulated by urolithin B. This pattern of discordant regulation suggests the two metabolites are not interchangeable, and that the net effect of a polyphenol-rich diet could depend on the relative abundance of each compound in an individual’s circulation.

Two of the oppositely regulated genes carry particular weight. IL-17B, an inflammatory signaling molecule, was decreased by roughly 49 percent under urolithin A but increased by about 45 percent under urolithin B. Recent work on dystrophinopathies has identified IL-17B as a biomarker of active muscle regeneration, enriched in regenerating fibers rather than in quiescent tissue. The authors interpret the opposing regulation not as a simple pro- versus anti-inflammatory split, but as evidence that the two compounds tune different inflammatory and regenerative programs: urolithin A may dampen the chronic low-grade inflammation implicated in sarcopenia, while urolithin B may nudge cells toward a remodeling state in which a controlled inflammatory component is part of repair. NQO1, meanwhile, encodes an enzyme that defends cells against oxidative stress by reducing quinones and preventing reactive oxygen species from forming. Its induction by urolithin A fits neatly with that compound’s established role in mitochondrial maintenance, whereas its suppression by urolithin B raises open questions about how anabolic signaling and oxidative defense are balanced under the second metabolite.

Pathway analysis sharpened the contrast. In urolithin A-treated cells, the most affected canonical pathways included inositol phosphate metabolism, calcium signaling and protein glycosylation routes, with most showing predicted inhibition. The authors propose that moderate inhibition of the inositol phosphate pathway, which is tightly linked to mitochondrial function through signaling molecules such as IP3, could trigger a compensatory boost in mitophagy and mitochondrial biogenesis, consistent with urolithin A’s known benefits. The glycosylation findings matter too, because protein glycosylation is now recognized as essential for maintaining normal muscle structure, and glycosylation defects are linked to muscle disease. Urolithin B told a different story: it strongly activated cholesterol biosynthesis and the mevalonate pathway, moderately activated adipogenesis, suppressed eicosanoid signaling in a way that could reduce inflammatory lipid mediators, and up-regulated CXCR4 signaling, a pathway recently shown to be critical for satellite cell activation, proliferation and self-renewal during muscle regeneration.

Validation experiments in cells from a subset of four donors confirmed several of these signals. Quantitative PCR showed that urolithin A increased expression of NOTCH1, a master regulator of muscle cell fate, as well as MYMX, a muscle-specific membrane protein involved in myogenic fusion, and PANX1, a newly identified regulator of myoblast proliferation and differentiation, while dose-dependently reducing FGF9 and ICAM5. Urolithin B was ineffective on these particular genes. Both compounds, however, dose-dependently reduced production of TGFBI, a protein associated with skeletal muscle remodeling, measured by ELISA in the culture supernatant. Live-cell imaging with label-free microscopy added a phenotypic dimension: fusion-like events appeared as early as six hours after treatment with either compound, and after 24 hours both treated conditions showed fewer isolated mononucleated cells than controls, consistent with enhanced incorporation of myoblasts into multinucleated myotubes.

The authors are careful to frame the work as mechanistic and exploratory rather than definitive. The myotubes were derived from post-mortem tissue, which may not fully mirror living muscle, although the use of expanded CD56-positive satellite cells, excellent RNA integrity and prior evidence that such cells retain functional competence mitigate that concern. The anonymized tissue source also meant detailed clinical phenotyping was unavailable, and the small, sex-unbalanced sample of six men and three women precluded formal analysis of age- or sex-specific responses. The short-term transcriptional data likewise cannot predict whether urolithin B’s activation of lipid-related pathways would be beneficial or, if chronically sustained in muscle, would contribute to the fatty infiltration associated with declining muscle quality. Still, the study sketches a compelling division of labor: urolithin A as a candidate for combating mitochondrial dysfunction and chronic inflammation in ageing muscle, and urolithin B as a potential ally for regeneration and repair after injury or surgery. The distinct yet complementary profiles raise the possibility of combination strategies targeting both the degenerative and regenerative faces of muscle decline, and they add a new layer to the growing science of the gut-muscle axis, in which the microbes of the colon may quietly shape how our muscles age.

Subject of Research: Transcriptomic effects of the gut microbial metabolites urolithin A and urolithin B on human skeletal muscle cells in relation to sarcopenia

Article Title: Exploring the Impact of Urolithins A and B on Muscle Health: A Transcriptomic Analysis in Human Myotubes

Article References: Henrotin, Y., Florin, A., Sanchez, C., Centonze, P., Coelho, T. P., Bekisz, S., Dubuc, J.-E., Galand, O., & Lambert, C. (2026). Exploring the Impact of Urolithins A and B on Muscle Health: A Transcriptomic Analysis in Human Myotubes. Journal of Cachexia, Sarcopenia and Muscle, 17(5), Article e70385. https://doi.org/10.1002/jcsm.70385

Image Credits: AI Generated

DOI: 10.1002/jcsm.70385

Keywords: urolithin A, urolithin B, sarcopenia, skeletal muscle, gut microbiota, ellagitannins, mitophagy, transcriptomics, myotubes, muscle regeneration, pomegranate polyphenols, inflammation

HFpEF, characterized by the heart’s inability to relax properly despite retaining normal contraction force, contributes significantly to cardiovascular morbidity and mortality worldwide. Current treatments remain limited, thus prompting intense investigation into novel molecular targets. The new research focuses on the AMPK–mTOR signaling axis, a crucial regulator of cellular energy homeostasis and autophagy.

The study demonstrated that Urolithin A activates AMPK, a master kinase that senses cellular energy deficits. Activation of AMPK subsequently inhibits the mechanistic target of rapamycin (mTOR), a protein kinase that suppresses autophagy when nutrients are abundant. This inhibition effectively lifts the brake on mitophagy, a specialized form of autophagy responsible for the selective removal of damaged mitochondria, thereby restoring mitochondrial quality control in cardiac cells.

Crucially, the enhancement of mitophagy attenuates pathological cardiac remodeling—structural and functional changes in the heart muscle that underlie HFpEF progression. Improved mitochondrial clearance prevents the accumulation of dysfunctional organelles, reducing oxidative stress and preserving cardiomyocyte function.

Moreover, the investigation revealed that Urolithin A also influences the gut–ceramide axis, linking metabolic signaling between intestinal microbiota and cardiac tissue. Ceramides, sphingolipid metabolites known to promote inflammation and insulin resistance, are modulated by gut-derived factors. By reshaping this axis, Urolithin A diminishes ceramide-driven deleterious effects, further contributing to cardiac protection.

Experimental models showed significant amelioration of cardiac remodeling following Urolithin A treatment, highlighting its promise as a novel therapeutic agent. This dual mechanism—restoring mitophagy via the AMPK–mTOR pathway and regulating systemic metabolic crosstalk via the gut–ceramide axis—positions Urolithin A as a multifaceted candidate against heart failure syndromes.

The findings open avenues for targeted therapies that harness endogenous cellular recycling processes and metabolic communication networks to counteract HFpEF. Future clinical trials are anticipated to evaluate the safety and efficacy of Urolithin A in human patients.

This study not only enriches our understanding of heart failure pathophysiology but also underscores the intricate interplay between cellular quality control and systemic metabolism. As such, Urolithin A heralds a new era in cardiometabolic therapeutics, bridging nutraceutical science and molecular cardiology.

Subject of Research: Heart failure with preserved ejection fraction (HFpEF) and mitophagy mechanisms

Article Title: Urolithin A activates mitophagy via the AMPK–mTOR axis and modulates the gut–ceramide axis to ameliorate cardiac remodeling in HFpEF

Article References:
Song, H., Yun, C., Choi, Y. et al. Urolithin A activates mitophagy via the AMPK–mTOR axis and modulates the gut–ceramide axis to ameliorate cardiac remodeling in HFpEF. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01776-2

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01776-2

The human gastrointestinal tract interfaces directly with trillions of microbes, rendering the gut a key hub of immune signaling and homeostasis. To maintain a balanced environment, epithelial cells lining the gut coordinate complex defense mechanisms that both protect against pathogens and tolerate beneficial microbes. Among these regulatory gateways, the NLRP6 inflammasome has emerged as a pivotal player in mucosal immunity, though the precise modulatory signals governing its activity have remained partially elusive.

Urolithin A (UA) is a microbiota-derived metabolite generated from dietary polyphenols such as ellagitannins abundant in pomegranates, berries, and nuts. Previous studies have attributed various health-promoting effects to UA including anti-inflammatory and anti-aging benefits; however, the underlying molecular pathways by which UA influences intestinal immunity have not been fully clarified until now. The new study delves deeply into these mechanisms, revealing a signaling axis that could be harnessed therapeutically to bolster gut health.

Central to the findings is the role of the aryl hydrocarbon receptor, a ligand-activated transcription factor widely expressed in intestinal epithelial cells and immune compartments. Known for detecting environmental toxins, AHR also senses endogenous and microbial metabolites to fine-tune immune responses. Ghosh and colleagues demonstrate that Urolithin A functions as a potent ligand for AHR, triggering downstream gene expression responsible for activating NLRP6 inflammasomes.

The inflammasome complex NLRP6 has been recognized for its role in promoting IL-18 secretion and maintaining epithelial cell homeostasis, thereby preventing dysbiosis and inflammatory bowel diseases. However, explicit understanding of how microbial metabolites impact NLRP6 activation has remained elusive, until the present study. By employing sophisticated molecular and cellular assays combined with in vivo models, the researchers establish that UA-mediated AHR activation modulates NLRP6-dependent pathways, resulting in enhanced secretion of mucosal immune factors and reinforcement of tight junction proteins that seal the gut barrier.

The study’s comprehensive approach involved exposing intestinal epithelial cell cultures to Urolithin A, observing a dose-dependent increase in AHR activation and subsequent transcriptional upregulation of NLRP6 and its effector molecules. Additionally, genetic ablation of AHR abolished these effects, affirming the receptor’s indispensable role in UA’s immunomodulatory capacity. Furthermore, in mouse models, oral administration of UA led to fortified gut barrier integrity, reduced intestinal permeability, and a balanced microbial milieu, thus demonstrating translational relevance.

By strategically modulating the AHR-NLRP6 axis, Urolithin A not only curtails excessive inflammatory signaling but also enhances mucosal defenses, showcasing a dual mechanism that safeguards intestinal health. These insights advance our comprehension of host-microbe interactions and underscore dietary metabolites’ potential as precision therapeutics that orchestrate immune homeostasis at mucosal surfaces.

Of particular interest is how NLRP6 activation by UA affects downstream cytokine networks, primarily involving IL-18—a key cytokine implicated in epithelial repair and antimicrobial defense. Enhanced IL-18 secretion amplifies epithelial renewal and maintains a resilient barrier against pathogenic incursions, thereby mitigating risks associated with chronic intestinal inflammation. This nuanced understanding of the cytokine milieu enriches prospects for targeting inflammatory bowel diseases and other gut disorders.

Moreover, the researchers highlight that Urolithin A supplementation offers a novel dietary intervention strategy by complementing the gut’s intrinsic immune defenses. Unlike classical immunosuppressive treatments, modulating the AHR-NLRP6 axis through UA preserves immune vigilance and mucosal tolerance, suggesting fewer adverse effects and sustained gut symbiosis. This paradigm shift could revolutionize dietary therapeutics aimed at maintaining intestinal homeostasis in both healthy and diseased states.

The study also illuminates how UA’s immunoregulatory effects cascade beyond epithelial cells to influence resident immune populations such as innate lymphoid cells and macrophages, although these dimensions warrant further exploration. By mediating epithelial-immune crosstalk, UA potentially orchestrates broader systemic immunity, linking gut health intimately to overall wellness.

Importantly, the research highlights that this metabolite-driven signaling cascade can be influenced by dietary patterns that affect polyphenol availability and microbiota composition. This insight accentuates the significance of personalized nutrition, where modulation of dietary intake can tailor gut-derived metabolite profiles and, in turn, fine-tune mucosal immunity through pathways like AHR-NLRP6.

The authors conclude by noting that their discovery opens fruitful avenues for developing UA-based or AHR-targeting therapeutics designed to reinforce gut barrier function. Such treatments could prove invaluable for patients suffering from conditions marked by compromised intestinal integrity, such as Crohn’s disease, ulcerative colitis, and even systemic disorders linked to gut dysbiosis.

In sum, this pivotal study advances the frontier of mucosal immunology by linking the dietary metabolite Urolithin A with aryl hydrocarbon receptor-dependent activation of NLRP6 inflammasomes. By decoding this intricate molecular dialogue, researchers have charted a promising path toward leveraging endogenous metabolites to promote intestinal health, offering exciting prospects for novel dietary and pharmacological interventions in gut-associated diseases.

As gut health increasingly gains recognition as a linchpin of systemic wellbeing, unraveling the molecular underpinnings of metabolite-immune crosstalk heralds a new era of therapeutic opportunities. The insights provided by Ghosh and colleagues exemplify how integrative research bridging microbiota metabolism and immunology can yield innovative strategies to sustain and restore health at the critical mucosal interface.

Ultimately, translating these experimental insights into clinical applications will require comprehensive human trials and further mechanistic studies. However, the foundational groundwork laid by this investigation effectively spotlights Urolithin A as a potent modulator of gut immunity operating through the AHR-NLRP6 axis, emphasizing the therapeutic value of harnessing host-microbe metabolic cross-talk in medicine’s future.

Subject of Research: The interaction between Urolithin A and intestinal immunity, focusing on aryl hydrocarbon receptor (AHR) activation and NLRP6 inflammasome-mediated pathways in intestinal epithelial cells.

Article Title: Urolithin A activates aryl hydrocarbon receptor-NLRP6-mediated pathways in intestinal epithelial cells to modulate mucosal immunity and strengthen gut barrier integrity.

Article References:
Ghosh, S., Vanwinkle, Z.M., Bodduluri, S.R. et al. Urolithin A activates aryl hydrocarbon receptor-NLRP6-mediated pathways in intestinal epithelial cells to modulate mucosal immunity and strengthen gut barrier integrity. Nat Commun 17, 5411 (2026). https://doi.org/10.1038/s41467-026-73760-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-026-73760-3